Safety of fenfluramine in children under 2 with Dravet syndrome
Part of Brain & nervous system clinical trials.
This trial tests the safety of a medicine called fenfluramine for children under 2 years old with Dravet syndrome. It aims to see if fenfluramine can help control seizures in very young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 12 and 23 months old.
- Your child must have Dravet syndrome or a specific change in the SCN1A gene.
- Your child must have tried at least one seizure medicine (not a sodium channel blocker) that didn't work.
- Your child must not have certain heart valve problems (like mitral or aortic valve regurgitation).
- Your child must not have failure to thrive (very low weight or poor weight gain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a reduced, home-based EEG monitoring device can help doctors safely adjust the dose of fenfluramine, a treatment for seizures in Dravet syndrome and Lennox-Gastaut syndrome. Participation may help find the right dose with fewer hospital visits.
This early-phase trial tests an experimental medicine called RC001 in children with Dravet syndrome caused by SCN1A gene changes. The goal is to see if RC001 is safe and how the body processes it, with the hope of reducing seizures.
This study looks for certain substances in the blood (called biomarkers) that may show how Dravet syndrome affects the brain. The goal is to better understand the condition and possibly improve future care.
This study looks at what happens when children with Dravet or Lennox Gastaut syndrome switch from a homemade or artisanal CBD product to Epidiolex, a prescription CBD. The goal is to see if the switch is safe and helps control seizures.
This study tests whether the drug fenfluramine can reduce the risk of sudden unexpected death (SUDEP) in people with Dravet syndrome who have generalized convulsive seizures. It aims to see if a lower dose can still prevent seizures and protect the heart and breathing during a seizure.
This Phase 2 trial studies fenfluramine to treat infantile spasms that haven’t improved after standard medicines (ACTH and vigabatrin). If you/your child has ongoing seizures, the study may offer another treatment option and will monitor safety closely, especially heart-related side effects.
Hear when a new Dravet Syndrome (DS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.